Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for .
Oyster Point Pharma, Inc.May 1, 2021 GMT
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data analyses from its Phase 3 ONSET-2 clinical trial evaluating OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting, being held on May 1-5.